オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

troy laboratories pty ltd - gentamicin as gentamicin sulfate - parenteral liquid/solution/suspension - gentamicin as gentamicin sulfate antibiotic active 100.0 mg/ml - antibiotic & related - cat - not pregnant | dog - not pregnant | horse - not pregnant - bacterial infection | amoxycillin sensitive bacteria | associated with viral disease | gram negative organisms | gram positive organisms | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

カナダ - 英語 - Health Canada

baxter corporation - gentamicin (gentamicin sulfate) - solution - 1.2mg - gentamicin (gentamicin sulfate) 1.2mg - aminoglycosides

カナダ - 英語 - Health Canada

baxter corporation - gentamicin (gentamicin sulfate) - solution - 1mg - gentamicin (gentamicin sulfate) 1mg - aminoglycosides

カナダ - 英語 - Health Canada

baxter corporation - gentamicin (gentamicin sulfate) - solution - 1.6mg - gentamicin (gentamicin sulfate) 1.6mg - aminoglycosides

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

cardinal health - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg) - gentamicin 10 mg in 1 ml

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

covetrus north america - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - indications: gentamicin sulfate with betamethasone valerate otic solution is indicated for the treatment of acute and chronic canine otitis externa and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin. contraindications: if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. this preparation should not be used in conditions where corticosteroids are contraindicated. do not administer parenteral corticosteroids during treatment with gentamicin sulfate with betamethasone valerate otic solution.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - gentamicin sulfate 65mg (gentamicin sulfate 65 mg/ml (bp) equivalent to 40mg/ml (40,000iu) gentamicin); gentamicin sulfate 65mg (gentamicin sulfate 65 mg/ml (bp) equivalent to 40mg/ml (40,000iu) gentamicin) - solution for injection - 40 mg/ml - active: gentamicin sulfate 65mg (gentamicin sulfate 65 mg/ml (bp) equivalent to 40mg/ml (40,000iu) gentamicin) excipient: disodium edetate dihydrate sodium hydroxide sulfuric acid water for injection active: gentamicin sulfate 65mg (gentamicin sulfate 65 mg/ml (bp) equivalent to 40mg/ml (40,000iu) gentamicin) excipient: disodium edetate dihydrate sodium methyl hydroxybenzoate sodium propyl hydroxybenzoate water for injection - dbl™ gentamicin injection bp is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa proteus species (indole positive and indole negative) escherichia coli klebsiella - enterobacter - serratia species staphylococcus species (coagulase positive and coagulase negative) dbl™ gentamicin injection bp should be considered for the treatment of the following conditions when caused by susceptible organisms: septicaemia respiratory tract infections infected wounds, bone and soft tissue infections including peritonitis, septic abortion and burns complicated by sepsis urinary tract infections (recurrent, complicated) dbl™ gentamicin injection bp is not routinely indicated in the initial treatment of uncomplicated urinary tract infections unless the organism is resistant to other less toxic antibacterials. dbl™ gentamicin injection bp may be considered as initial therapy in suspected or confirmed gram negative infections and therapy may be instituted before obtained results of susceptibility testing. if anaerobic organisms are suspected, additional antimicrobial therapy should be added to the gentamicin regime.

カナダ - 英語 - Health Canada

hospira healthcare ulc - gentamicin (gentamicin sulfate); sodium chloride - solution - 1.2mg; 9mg - gentamicin (gentamicin sulfate) 1.2mg; sodium chloride 9mg - aminoglycosides

カナダ - 英語 - Health Canada

hospira healthcare ulc - gentamicin (gentamicin sulfate); sodium chloride - solution - 0.8mg; 9mg - gentamicin (gentamicin sulfate) 0.8mg; sodium chloride 9mg - aminoglycosides